Abstract
During the last five decades, enormous advances in treatment modalities for cancer and a better understanding of cancer cell biology have been accomplished but the prognosis of patients carrying malignant gliomas still remains poor despite hundreds of clinical trials have been carried out. In this article we review phase II clinical trials that have been completed and published in PubMed during 2011 in order to investigate potential reasons of clinical failure. We suggest that a translational gap, defined as a failure to translate basic research into clinical trials design may explain the poor outcome of phase II clinical trials.
Keywords: Clinical trial, Glioma, phenotype, stem cells, stem cell theory, stemness.
Graphical Abstract
Anti-Cancer Agents in Medicinal Chemistry
Title:Translational Gap in Glioma Research
Volume: 14 Issue: 8
Author(s): Chi Ma, Gang Zhao, Mabel Hilda Cruz, Ake Siden and Juan Sebastian Yakisich
Affiliation:
Keywords: Clinical trial, Glioma, phenotype, stem cells, stem cell theory, stemness.
Abstract: During the last five decades, enormous advances in treatment modalities for cancer and a better understanding of cancer cell biology have been accomplished but the prognosis of patients carrying malignant gliomas still remains poor despite hundreds of clinical trials have been carried out. In this article we review phase II clinical trials that have been completed and published in PubMed during 2011 in order to investigate potential reasons of clinical failure. We suggest that a translational gap, defined as a failure to translate basic research into clinical trials design may explain the poor outcome of phase II clinical trials.
Export Options
About this article
Cite this article as:
Ma Chi, Zhao Gang, Cruz Hilda Mabel, Siden Ake and Yakisich Sebastian Juan, Translational Gap in Glioma Research, Anti-Cancer Agents in Medicinal Chemistry 2014; 14 (8) . https://dx.doi.org/10.2174/1871520614666140825110907
DOI https://dx.doi.org/10.2174/1871520614666140825110907 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Delivery of Nanoparticles for Treatment of Brain Tumor
Current Drug Metabolism CD95 Signaling in Cancer Treatment
Current Pharmaceutical Design Nanotechology-Based Strategies to Enhance the Efficacy of Photodynamic Therapy for Cancers
Current Drug Metabolism Aquaporins and Roles in Brain Health and Brain Injury
Mini-Reviews in Medicinal Chemistry Phosphatidylinositol 3-Kinase Isoforms as Novel Drug Targets
Current Drug Targets Rational Combination of Targeted Therapies As A Strategy to Overcome The Mechanisms of Resistance to Inhibitors of EGFR Signaling
Current Pharmaceutical Design Pharmacological Applications of Antioxidants: Lights and Shadows
Current Drug Targets A Multi-targeted Natural Flavonoid Myricetin Suppresses Lamellipodia and Focal Adhesions Formation and Impedes Glioblastoma Cell Invasiveness and Abnormal Motility
CNS & Neurological Disorders - Drug Targets Rapamycin-loaded Immunoliposomes Functionalized with Trastuzumab: A Strategy to Enhance Cytotoxicity to HER2-positive Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Roles of p75NTR in Maintaining Brain Hemostasis and the Implications for p75NTR-targeted Therapies
Current Alzheimer Research Cancer and Aids: New Trends in Drug Design and Chemotherapy
Current Computer-Aided Drug Design <i>Circular RNA NF1-419</i> Inhibits Proliferation and Induces Apoptosis by Regulating Lipid Metabolism in Astroglioma Cells
Recent Patents on Anti-Cancer Drug Discovery Hypoxia in Du-145 Prostate Cancer Xenografts After Estramustine Phosphate and Radiotherapy
Current Radiopharmaceuticals Bioactive Triterpenic Acids: From Agroforestry Biomass Residues to Promising Therapeutic Tools
Mini-Reviews in Organic Chemistry Disease-Responsive Drug Delivery: The Next Generation of Smart Delivery Devices
Current Drug Metabolism 2D, 3D, G-QSAR and Docking Studies of Thiazolyl-pyrazoline Analogues as Potent (Epidermal Growth Factor Receptor-tyrosine Kinase) EGFR-TK Inhibitors
Letters in Drug Design & Discovery The Bax Inhibitor-1 (BI-1) Family in Apoptosis and Tumorigenesis
Current Molecular Medicine Update on Pharmacologic Retinal Vascular Toxicity
Current Pharmaceutical Design Expression and Function of Kruppel Like-Factors (KLF) in Carcinogenesis
Current Genomics Targeting the Multidrug ABCG2 Transporter with Flavonoidic Inhibitors: In Vitro Optimization and In Vivo Validation
Current Medicinal Chemistry